"AI helped us do 160 years of biology work in two months." When Harvard Medical School geneticist David Sinclair said this on Joe Rogan's podcast, Rogan asked back, "What?!" The X post with that clip spread with over 200,000 views and 3,900 likes. The remark comes from the episode The Joe Rogan Experience #2537, released on August 7, 2026.
The Line That Surprised Rogan, and the Actual Context
Sinclair made the remark while describing research to replace three "cocktail" drugs that reverse aging with a single molecule. He said, "You need to find one molecule that does three or four things in the cell at the same time." The key point is that in choosing this candidate, AI was used to filter a huge number of molecules by computer.
160 Years? Only on a Podcast?
Sinclair is a Harvard Medical School professor known for sirtuin and NAD research, author of the bestseller Lifespan, and co-founder of companies including Life Biosciences. But he is also someone who has been criticized by academics several times for exaggerated claims. In 2024 he stepped down as president of an aging research society (AHLR), and fellow scientist Matt Kaeberlein has said, "He often gets ahead of himself and says things that are not true."
Where AI Is Actually Changing Drug Discovery
The practical work behind the remark is screening based on molecular docking (virtual docking). Billions to trillions of candidate molecules are docked against a target enzyme by computer, then narrowed to 100 to 200 candidates that need lab validation. This ties in with a case introduced by Peter Diamandis and others, and shows a real trend that greatly cuts time in the early stage of drug candidate discovery.
The 160-Year Figure Differs by Interview
Sinclair has repeated the same "160 years" analogy on several podcasts, and the number of molecules screened (trillions vs. about 8 billion) and the time taken (one month vs. two months) differed slightly by interview. The original remark itself and the broader trend of "using AI to accelerate drug screening" are real, but exact figures and peer-reviewed data have not been confirmed. It is also worth keeping in mind, when taking in his remarks, that he has commercial ties to companies such as an NMN supplement maker.